BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsEarnings

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6

Related news

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

SNDXSyndax Pharmaceuticals2026-06-11 11:00 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Stock data

Close
19.76 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States